Show simple item record

dc.contributor.authorJourdan, Men_US
dc.contributor.authorCren, Men_US
dc.contributor.authorSchafer, Pen_US
dc.contributor.authorRobert, Nen_US
dc.contributor.authorDuperray, Cen_US
dc.contributor.authorVincent, Len_US
dc.contributor.authorCeballos, Pen_US
dc.contributor.authorCartron, Gen_US
dc.contributor.authorRossi, JFen_US
dc.contributor.authorMoreaux, Jen_US
dc.contributor.authorChopra, Ren_US
dc.contributor.authorKlein, Ben_US
dc.date.accessioned2017-05-23T14:59:06Z
dc.date.issued2016-05en_US
dc.identifier.citationOncotarget, 2016, 7 (19), pp. 28096 - 28111en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/645
dc.identifier.eissn1949-2553en_US
dc.identifier.doi10.18632/oncotarget.8581en_US
dc.description.abstractThalidomide, lenalidomide and pomalidomide have greatly improved the outcome of patients with multiple myeloma. However, their effects on plasma cells, the healthy counterpart of myeloma cells, are unknown. Here, we investigated lenalidomide effects on normal human plasma cell generation using an in vitro model. Lenalidomide inhibited the generation of pre-plasmablasts and early plasma cells, while it moderately affected plasmablast production. It also reduced the expression level of Ikaros, Aiolos, and IRF4 transcription factors, in plasmablasts and early plasma cells. This suggests that their differential sensitivity to lenalidomide is not due to a difference in Ikaros or Aiolos degradation. Lenalidomide also inhibited long-lived plasma cell generation, but did not impair their long-term survival once generated. This last observation is in agreement with the finding that lenalidomide treatment for 3-18 months did not affect the bone marrow healthy plasma cell count in allografted patients with multiple myeloma. Our findings should prompt to investigate whether lenalidomide resistance in patients with multiple myeloma could be associated with the emergence of malignant plasmablasts or long-lived plasma cells that are less sensitive to lenalidomide.en_US
dc.formatPrinten_US
dc.format.extent28096 - 28111en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleDifferential effects of lenalidomide during plasma cell differentiation.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-03-28en_US
rioxxterms.versionofrecord10.18632/oncotarget.8581en_US
rioxxterms.licenseref.startdate2016-05en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfOncotargeten_US
pubs.issue19en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.volume7en_US
pubs.embargo.termsNo embargoen_US
dc.contributor.icrauthorChopra, Rajeshen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/